SUPPLEMENTARY FIGURES




Figure S1. Predicted foldedness of selected model proteins.

- 5 FoldIndex (Prilusky et al., 2005) analysis of *B. subtilis* proteins used in mSA-fusion constructs. Structurally ordered sequences (green) and disordered regions (red) are highlighted. The selected proteins include: NrdI (a flavodoxin-like protein component of ribonucleoside reductases) (Cotruvo and Stubbe, 2010), TagD (glycerol-3-phosphate cytidyltranferase involved in teichoic acid synthesis) (Park et al., 1993),
- 10 NusA (transcription factor involved in pausing/termination) (Gusarov and Nudler, 2001) and Kre (also known as YkyB, a regulator of the competence transcription factor ComK) (Gamba et al., 2015). PDB structures are available for *B. subtilis* NrdI bound to riboflavin monophosphate (PDB: 1RLJ); *B. subtilis* TagD dimer bound to cytidine-5'-triphosphate (PDB: 1COZ); *Thermotoga maritima* NusA, which has 51% identity to
- 15 *B. subtilis* NusA (PDB: 1HH2).




Figure S2. EM analysis of *B. subtilis* ClpC_{DWB}.

20

(**A**) Negative stain EM analysis of *B. subtilis* ClpC_{DWB} in the absence of BacPROTAC-1: representative micrograph from the 1,004 collected (scale bar = 350 Å). (**B**) Cryo-EM analysis of *B. subtilis* ClpC_{DWB} in the presence of BacPROTAC-1: a representative micrograph from the 4,455 collected (scale bar = 420 Å). (**C**) FSC curves of the final maps obtained by cryo-EM analysis, showing a resolution of 10 Å for the tetramer of hexamers map and 3.7 Å for the single hexamer map. (**D**) Angular distribution of the particles used to reconstruct the single hexamer map. (**E**) Local resolution map for the single hexamer in different orientations.




Figure S3. Nucleotide binding sites of the six ClpC_{DWB} **protomers.**

The different panels show the modelled nucleotide in each active site pocket and some of the crucial residues involved in ATP hydrolysis and ATP/ADP interaction. Contacts between ATP γ -phosphate and Arg fingers in D1 (R332-R333) and D2 (R704) are indicated (*) for the ATP-bound sites, while distances between Arg fingers C α and ADP β phosphate are shown for ADP hound sites. The cruc EM map is represented

35 ADP β-phosphate are shown for ADP-bound sites. The cryo-EM map is represented as grey surface around the modelled protein structure.





Figure S4. Conservation of pArg binding sites in Gram-positive bacteria and 40 mycobacteria.

(A) Sequence alignment of ClpC_{NTDs} from different species (*B. subtilis*, *S. aureus*, *M. smegmatis*, *M. leprae*, *M. tuberculosis*). Residues interacting with pArg are circled in black and marked by an arrow. (B) Structure of pArg-bound *B. subtilis* ClpC_{NTD} (colored green, PDB: 5HBN) superposed with *M. tuberculosis* ClpC1_{NTD} (colored magenta, PDB: 3WDB). (C) Zoomed view of the two pArg binding sites shows that crucial residues interacting with the phospho-guanidino group are conserved in *M. tuberculosis*.




50 Figure S5. Characterization of compounds and BacPROTACs binding ClpC1_{NTD}.

(A) Representative ITC titration of BacPROTAC-1 (400 μM loaded in the syringe) against ClpC1_{NTD} (22 μM loaded in the cell); reported K_D value represents the average ± standard deviation of three independent measurements. (B) Representative ITC titration of ClpC1_{NTD} (406 μM loaded in the syringe) against sCym-1 (30 μM loaded in the cell), reported K_D value represents the average ± standard deviation of three independent measurements. (C) Representative ITC titration of ClpC1_{NTD} (356 μM loaded in the syringe) against BacPROTAC-2 (30 μM loaded in the cell), reported K_D value represents the average ± standard deviation of two independent measurements.
(D) Representative ITC titration of BRDT_{BD1} (124 μM loaded in the syringe) against BacPROTAC-3 (15 μM loaded in the cell); reported K_D value represents the average ± standard deviation of the average ± standard deviation of the syringe) against BacPROTAC-3 (30 μM loaded in the syringe) against bacPROTAC-3 (15 μM loaded in the cell); reported K_D value represents the average ± standard deviation of three independent measurements. (E) Representative ITC titration of ClpC1_{NTD} (392 μM loaded in the syringe) against BacPROTAC-3 (30 μM

loaded in the cell); reported K_D value represents the average ± standard deviation of five independent measurements. (F) SEC analysis of a stoichiometric
 BRDT_{BD1}:ClpC1_{NTD} mixture in the presence (solid line) or absence (dashed line) of BacPROTAC-3. The two proteins elute at the same volume also in the absence of BacPROTAC because of their similar size, however BacPROTAC-3 addition mediates formation of an additional peak compatible with the elution volume expected for the BRDT_{BD1}:BacPROTAC-3:ClpC1_{NTD} ternary complex. Coomassie stained SDS-PAGE

70 gel of the collected peak fractions is shown. BRDT_{BD1} and ClpC1_{NTD} have identical electrophoretic mobility and are thus not distinguishable on the Coomassie stained gel.



75 Figure S6. BacPROTAC-3-induced degradation is stereospecific.

80

JQ1 binding to BRDT_{BD1} is stereo-specific (Filippakopoulos et al., 2010). Only the JQ1-(*S*) enantiomer is active (eutomer), while the JQ1-(*R*) enantiomer binds with an approximately 60-fold lower affinity (distomer). (**A**) Chemical structure of the BacPROTAC-3 distomer, synthesized using JQ1-(*R*). (**B**) *In vitro* degradation assay using *M. smegmatis* ClpC1P1P2 analyzed after 2 hours incubation showing that BRDT_{BD1} not significantly degraded in presence of 100-0.1 μ M BacPROTAC-3 distomer, in contrast to the BacPROTAC-3 eutomer (**Figure 5B**).




Figure S7. BRDT_{BD1} levels detected by capillary Western blot upon BacPROTAC treatment of *M. smegmatis* cells.

85

Electropherograms showing intensity of the chemiluminescent signal plotted against the apparent molecular weight detected using anti-BRDT and anti-RpoB antibodies.

(A-F) Detected peaks for lysates of a *M. smegmatis* culture expressing BRDT_{BD1} after each treatment (30 minutes) in triplicate: (A) DMSO, (B) 100 μ M BacPROTAC-3, (C)

90 10 μM BacPROTAC-3, (D) 1 μM BacPROTAC-3, (E) 100 μM sCym-1, (F) 100 μM JQ1. (G) Bar chart showing quantification of detected RpoB peaks (loading control) from three independent experiments normalized to DMSO treatment (dark grey bar) and plotted as mean ± standard deviation. Quantification of the BRDT_{BD1} peak is shown in Figure 5D.




Figure S8. Uncropped assay gels. Uncropped Coomassie stained SDS-PAGE gels shown in (A) **Figure 1G** and **1H**; (B) **Figure 4B** and **4H**; (C) **Figure 5B**.

100 SUPPLEMENTARY TABLES

Table S1: Crystallographic analysis of ClpC1_{NTD}:sCym-1 complex. Data collection and refinement statistics

PDB ID	7AA4
Space group	<i>P</i> 1
Cell dimensions	
a, b, c (Å)	31.35, 33.68, 35.81
α, β, γ (°)	86.178, 94.216, 103.176
Resolution (Å) ^{a,b}	25 – 1.68 (1.72 – 1.68)
R _{meas(I)}	0.062 (0.112)
Ι/σ (Ι)	22.6 (12.5)
CC _{1/2}	0.998 (0.992)
Completeness (%)	93.8 (86.5)
Redundancy	5.8 (5.4)
Resolution (Å)	25 – 1.68
No. reflections	15,165
R _{work} / R _{free}	17.0 / 20.3
No. atoms	
protein	1254
ligand	66
water	192
B factors	
protein	11.9
ligand	13.5
water	23.0

R.m.s. deviations	
Bond lengths (Å)	0.006
Bond angles (°)	0.789

^aValues in parentheses are for highest-resolution shell.

^bDue to experimental constraints the resolution needed to be truncated to this resolution.

Table S2. Amino acid sequences of mSA fusion proteins.

Construct	Amino acid sequence
name	
mSA	MHHHHHHSSGVDLGTENLYFQSSQDLASAEAGITGTWYNQSGSTFTVTAGAD GNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTENCHSRTEW RGQYQGGAEARINTQWNLTYEGGSGPATEQGQDTFTKVKPSAASGSGSGSGS GS
mSA-Kre	MHHHHHHSSGVDLGTENLYFQSSQDLASAEAGITGTWYNQSGSTFTVTAGAD GNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTENCHSRTEW RGQYQGGAEARINTQWNLTYEGGSGPATEQGQDTFTKVKPSAASGSGSGSGS MDDHAYTKDLQPTVENLSKAVYTVNRHAKTAPNPKYLYLLKKRALQKLVKEGKG KKIGLHFSKNPRFSQQQSDVLISIGDYYFHMPPTKEDFEHLPHLGTLNQSYRNP KAQMSLTKAKHLLQEYVGMKEKPLVPNRQQPAYHKPVFKKLGESYF
mSA-Kre (Cryo-EM structure determination)	MSQDLASAEAGITGTWYNQSGSTFTVTAGADGNLTGQYENRAQGTGCQNSPY TLTGRYNGTKLEWRVEWNNSTENCHSRTEWRGQYQGGAEARINTQWNLTYE GGSGPATEQGQDTFTKVKPSAASGSGSGSGSGSGSGSGSGSGSDDHAYTKDLQ PTVENLSKAVYTVNRHAKTAPNPKYLYLLKKRALQKLVKEGKGKKIGLHFSKNP RFSQQQSDVLISIGDYYFHMPPTKEDFEHLPHLGTLNQSYRNPKAQMSLTKAKH LLQEYVGMKEKPLVPNRQQPAYHKPVFK KLGESYFHHHHHH
mSA-NrdI	MHHHHHHSSGVDLGTENLYFQSSQDLASAEAGITGTWYNQSGSTFTVTAGAD GNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTENCHSRTEW RGQYQGGAEARINTQWNLTYEGGSGPATEQGQDTFTKVKPSAASGSGSGSGS GSVVQIIFDSKTGNVQRFVNKTGFQQIRKVDEMDHVDTPFVLVTYTTNFGQVPA STQSFLEKYAHLLLGVAASGNKVWGDNFAKSADTISRQYQVPILHKFELSGTSK DVELFTQEVERVVTKSSAKMDPVK
mSA-TagD	MHHHHHHSSGVDLGTENLYFQSSQDLASAEAGITGTWYNQSGSTFTVTAGAD GNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTENCHSRTEW RGQYQGGAEARINTQWNLTYEGGSGPATEQGQDTFTKVKPSAASGSGSGSGS GSMKKVITYGTFDLLHWGHIKLLERAKQLGDYLVVAISTDEFNLQKQKKAYHSYE HRKLILETIRYVDEVIPEKNWEQKKQDIIDHNIDVFVMGDDWEGKFDFLKDQCEV VYLPRTEGISTTKIKEEIAGL
mSA-NusA	MHHHHHHSSGVDLGTENLYFQSSQDLASAEAGITGTWYNQSGSTFTVTAGAD GNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTENCHSRTEW RGQYQGGAEARINTQWNLTYEGGSGPATEQGQDTFTKVKPSAASGSGSGSGS GSMSSELLDALTILEKEKGISKEIIIEAIEAALISAYKRNFNQAQNVRVDLNRETGSI RVFARKDVVDEVYDQRLEISIEEAQGIHPEYMVGDVVEIEVTPKDFGRIAAQTAK

QVVTQRVREAERGVIYSEFIDREEDIMTGIVQRLDNKFIYVSLGKIEALLPVNEQM
PNESYKPHDRIKVYITKVEKTTKGPQIYVSRTHPGLLKRLFEIEVPEIYDGTVELKS
VAREAGDRSKISVRTDDPDVDPVGSCVGPKGQRVQAIVNELKGEKIDIVNWSSD
PVEFVANALSPSKVLDVIVNEEEKATTVIVPDYQLSLAIGKRGQNARLAAKLTGW
KIDIKSETDARELGIYPRELEEDDEPLFTEPETAESDE

Movie S1. Cryo-EM structure of activated ClpC in complex with substrate.

The movie shows the map of the tetramer of ClpC hexamers (10 Å) and the map obtained refining a single ClpC hexamer (3.7 Å). Both maps are colored by ClpC protomer. Continuous density is observed for a substrate peptide (colored yellow) along the ClpC channel, surrounded by Tyr-containing pore loops, as described in the main text.

120 **REFERENCES**

Cotruvo, J.A., Jr., and Stubbe, J. (2010). An active dimanganese(III)-tyrosyl radical cofactor in Escherichia coli class Ib ribonucleotide reductase. Biochemistry *49*, 1297-1309.

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse,
E.M., Keates, T., Hickman, T.T., Felletar, I., *et al.* (2010). Selective inhibition of BET bromodomains. Nature *468*, 1067-1073.

Gamba, P., Jonker, M.J., and Hamoen, L.W. (2015). A Novel Feedback Loop That Controls Bimodal Expression of Genetic Competence. PLoS Genet *11*, e1005047.

Gusarov, I., and Nudler, E. (2001). Control of intrinsic transcription termination by N 130 and NusA: the basic mechanisms. Cell *107*, 437-449.

Hofmann, F.T., Lindemann, C., Salia, H., Adamitzki, P., Karanicolas, J., and Seebeck, F.P. (2011). A phosphoarginine containing peptide as an artificial SH2 ligand. Chem Commun (Camb) *47*, 10335-10337.

Park, Y.S., Sweitzer, T.D., Dixon, J.E., and Kent, C. (1993). Expression, purification,
and characterization of CTP:glycerol-3-phosphate cytidylyltransferase from Bacillus subtilis. J Biol Chem 268, 16648-16654.

Prilusky, J., Felder, C.E., Zeev-Ben-Mordehai, T., Rydberg, E.H., Man, O., Beckmann, J.S., Silman, I., and Sussman, J.L. (2005). FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics *21*, 3435-3438.